EPRX
Eupraxia Pharmaceuticals Inc.
Price Chart
Latest Quote
$6.48
+0.19 (+3.02%)
Current Price
| Previous Close | $6.29 |
| Open | $6.45 |
| Day High | $6.53 |
| Day Low | $6.30 |
| Volume | 471,611 |
Stock Information
| Shares Outstanding | 65.33M |
| Total Debt | $2.01M |
| Cash Equivalents | $138.88M |
| Net Income | $-46.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $423.32M |
| EPS (TTM) | $-1.05 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $314.59M |
| Income | $-46.98M |
| Book/sh | $1.75 |
| Cash/sh | $2.13 |
| Employees | 49 |
Financial Ratios
| Quick Ratio | 18.95 |
| Current Ratio | 19.30 |
| Debt/Eq | 1.47 |
Returns & Margins
| ROA | -33.84% |
| ROE | -54.52% |
Ownership
| Insider Ownership | 14.22% |
| Institutional Ownership | 41.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.01 |
| P/B | 3.71 |
Analyst Data
| Recommendation | none |
| Target Price | $16.28 |
Technical Indicators
| SMA20 | $6.52 |
| SMA50 | $6.93 |
| SMA200 | $6.90 |
| RSI | 37.45 |
| ATR | 0.3881 |
| Shares Float | 50.32M |
| Short Ratio | 17.60 |
| Volatility | 1.48 |
| Rel Volume | 1.38 |
Performance History
| Week | +7.46% |
| Month | +3.02% |
| Quarter | -14.74% |
| 6 Months | +3.68% |
| YTD | -14.40% |
| Year | +51.76% |
| 10 Years | +119.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.48 | 471,600 |
| 2026-06-17 | $6.29 | 435,300 |
| 2026-06-16 | $6.03 | 594,600 |
| 2026-06-15 | $6.22 | 256,300 |
| 2026-06-12 | $6.04 | 141,100 |
| 2026-06-11 | $6.03 | 213,600 |
| 2026-06-10 | $5.92 | 219,000 |
| 2026-06-09 | $5.96 | 452,000 |
| 2026-06-08 | $5.99 | 312,200 |
| 2026-06-05 | $5.95 | 356,600 |
| 2026-06-04 | $6.45 | 352,800 |
| 2026-06-03 | $6.33 | 292,200 |
| 2026-06-02 | $6.65 | 296,600 |
| 2026-06-01 | $6.86 | 254,300 |
| 2026-05-29 | $7.09 | 194,200 |
| 2026-05-28 | $7.38 | 118,500 |
| 2026-05-27 | $7.18 | 170,900 |
| 2026-05-26 | $7.53 | 360,500 |
| 2026-05-22 | $7.10 | 904,100 |
| 2026-05-21 | $6.94 | 414,300 |
| 2026-05-20 | $6.37 | 214,100 |
| 2026-05-19 | $6.29 | 485,400 |
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
đ° Latest News
Eupraxia Pharmaceuticals Q1 Loss Narrows
MT Newswires âĸ 2026-05-12T21:21:46ZEupraxia Reports Latest 36-Week Results From Resolve Trial
MT Newswires âĸ 2026-04-21T11:32:46ZNew Strong Sell Stocks for April 2nd
Zacks âĸ 2026-04-02T10:03:00Z
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial
MT Newswires âĸ 2026-03-17T11:38:36ZEupraxia Pharmaceuticals Q4 Loss Widens
MT Newswires âĸ 2026-03-13T11:19:43ZEupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option
MT Newswires âĸ 2026-02-20T20:38:29ZEupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering
MT Newswires âĸ 2026-02-19T12:28:43ZHere's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation
Simply Wall St. âĸ 2026-02-05T17:06:12Z
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial
MT Newswires âĸ 2026-01-08T14:49:15ZAnalysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Hereâs Why
Insider Monkey âĸ 2025-12-05T03:09:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $603,573 | $1,170,173 | $982,856 |
| Total Expenses | $38,434,039 | $27,003,411 | $27,847,229 | $17,617,452 |
| Other Income Expense | $-1,565,038 | $704,356 | $-775,150 | $-822,255 |
| Net Non Operating Interest Income Expense | $1,412,516 | $556,370 | $-307,204 | $-551,057 |
| Interest Expense Non Operating | $0 | $603,573 | $1,170,173 | $982,856 |
| Operating Expense | $38,434,039 | $27,003,411 | $27,847,229 | $17,617,452 |
| General And Administrative Expense | $17,102,383 | $10,924,135 | $7,484,105 | $3,987,598 |
| Other Operating Expenses | - | - | - | $156,596 |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,576,143 | $-25,502,536 | $-28,220,796 | $-18,489,629 |
| Net Interest Income | $1,412,516 | $556,370 | $-307,204 | $-551,057 |
| Interest Income | $1,412,516 | $1,159,943 | $862,969 | $431,799 |
| Normalized Income | $-37,011,105 | $-26,206,892 | $-27,755,706 | $-17,667,374 |
| Net Income From Continuing And Discontinued Operation | $-38,576,143 | $-25,502,536 | $-28,220,796 | $-18,489,629 |
| Net Income Common Stockholders | $-38,576,143 | $-25,502,536 | $-28,220,796 | $-18,489,629 |
| Net Income | $-38,576,143 | $-25,502,536 | $-28,220,796 | $-18,489,629 |
| Net Income Including Noncontrolling Interests | $-38,605,652 | $-25,744,489 | $-28,966,006 | $-18,990,764 |
| Net Income Continuous Operations | $-38,605,652 | $-25,744,489 | $-28,966,006 | $-18,990,764 |
| Pretax Income | $-38,586,561 | $-25,742,685 | $-28,929,583 | $-18,990,764 |
| Special Income Charges | $-2,562 | $-336,971 | $-4,846 | $-6,637 |
| Interest Income Non Operating | $1,412,516 | $1,159,943 | $862,969 | $431,799 |
| Operating Income | $-38,434,039 | $-27,003,411 | $-27,847,229 | $-17,617,452 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $142,406 |
| Depreciation And Amortization In Income Statement | - | - | - | $142,406 |
| Depreciation Income Statement | - | - | - | $142,406 |
| Per Share | ||||
| Diluted EPS | $-1.03 | $-0.76 | $-1.17 | $-0.96 |
| Basic EPS | $-1.03 | $-0.76 | $-1.17 | $-0.96 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-310,060 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-36,783,806 | $-25,671,749 | $-26,828,733 | $-17,037,759 |
| Total Unusual Items | $-1,565,038 | $704,356 | $-775,150 | $-822,255 |
| Total Unusual Items Excluding Goodwill | $-1,565,038 | $704,356 | $-775,150 | $-822,255 |
| Reconciled Depreciation | $237,717 | $171,719 | $155,527 | $147,894 |
| EBITDA (Bullshit earnings) | $-38,348,844 | $-24,967,393 | $-27,603,883 | $-17,860,014 |
| EBIT | $-38,586,561 | $-25,139,112 | $-27,759,410 | $-18,007,908 |
| Diluted Average Shares | $39,956,133 | $33,930,575 | $24,146,623 | $19,285,447 |
| Basic Average Shares | $39,956,133 | $33,930,575 | $24,146,623 | $19,285,447 |
| Diluted NI Availto Com Stockholders | $-38,576,143 | $-25,502,536 | $-28,220,796 | $-18,489,629 |
| Minority Interests | $29,509 | $241,953 | $745,210 | $501,135 |
| Tax Provision | $19,091 | $1,804 | $36,423 | $0 |
| Gain On Sale Of Ppe | $-2,562 | $18,611 | $-4,846 | $-6,637 |
| Gain On Sale Of Security | $-1,562,476 | $1,041,327 | $-770,304 | $-815,618 |
| Research And Development | $21,331,656 | $16,079,276 | $20,363,124 | $13,629,854 |
| Selling General And Administration | $17,102,383 | $10,924,135 | $7,484,105 | $3,987,598 |
| Other Gand A | $5,773,257 | $4,755,829 | $4,161,174 | $936,028 |
| Insurance And Claims | $985,431 | $954,392 | $367,472 | $357,763 |
| Salaries And Wages | $10,343,695 | $5,213,914 | $2,955,459 | $2,693,807 |
| Other Special Charges | - | $355,582 | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $82,041,436 | $33,404,803 | $2,216,207 | $7,786,525 |
| Total Assets | $86,150,008 | $34,942,355 | $20,266,229 | $19,122,249 |
| Total Non Current Assets | $1,051,458 | $505,677 | $463,151 | $533,242 |
| Non Current Prepaid Assets | $64,332 | $80,761 | $6,904 | $2,492 |
| Current Assets | $85,098,550 | $34,436,678 | $19,803,078 | $18,589,007 |
| Prepaid Assets | $3,860,842 | $1,106,512 | $270,710 | $235,903 |
| Receivables | $674,226 | $228,872 | $190,612 | $89,715 |
| Taxes Receivable | $674,226 | $228,872 | $190,612 | $75,823 |
| Cash Cash Equivalents And Short Term Investments | $80,563,482 | $33,101,294 | $19,341,756 | $18,263,389 |
| Cash And Cash Equivalents | $80,563,482 | $33,101,294 | $19,341,756 | $18,263,389 |
| Cash Financial | $80,563,482 | $33,101,294 | $19,341,756 | - |
| Other Receivables | - | - | - | $13,892 |
| Debt | ||||
| Total Debt | $154,362 | $71,859 | $10,452,028 | $8,985,829 |
| Long Term Debt And Capital Lease Obligation | $75,910 | $0 | $0 | $8,856,008 |
| Current Debt And Capital Lease Obligation | $78,452 | $71,859 | $10,452,028 | $129,821 |
| Current Debt | - | - | $10,398,712 | $79,418 |
| Other Current Borrowings | - | - | $10,398,712 | $79,418 |
| Long Term Debt | - | - | - | $8,804,705 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,703,915 | $3,103,386 | $19,373,903 | $11,914,395 |
| Total Non Current Liabilities Net Minority Interest | $75,910 | $0 | $0 | $8,856,008 |
| Current Liabilities | $5,628,005 | $3,103,386 | $19,373,903 | $3,058,387 |
| Payables And Accrued Expenses | $5,549,553 | $3,031,527 | $8,063,247 | $2,415,265 |
| Payables | $1,519,862 | $1,493,981 | $5,036,423 | - |
| Other Payable | $1,518,256 | $1,493,981 | $5,000,000 | - |
| Total Tax Payable | $1,606 | $0 | $36,423 | $0 |
| Derivative Product Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $52,303,115 | $1,699,584 | $2,216,207 | $7,786,525 |
| Preferred Stock Equity | $29,738,321 | $31,705,219 | - | - |
| Total Equity Gross Minority Interest | $80,446,093 | $31,838,969 | $892,326 | $7,207,854 |
| Stockholders Equity | $82,041,436 | $33,404,803 | $2,216,207 | $7,786,525 |
| Gains Losses Not Affecting Retained Earnings | $-2,044,137 | $-4,160,555 | $-2,706,552 | $-2,786,366 |
| Other Equity Adjustments | $-2,044,137 | $-4,160,555 | $-2,706,552 | $-2,786,366 |
| Retained Earnings | $-169,579,974 | $-131,003,831 | $-105,501,295 | $-77,280,499 |
| Other | ||||
| Ordinary Shares Number | $51,939,206 | $35,641,603 | $27,282,165 | $21,593,145 |
| Share Issued | $51,939,206 | $35,641,603 | $27,282,165 | $21,593,145 |
| Tangible Book Value | $52,303,115 | $1,699,584 | $2,216,207 | $7,786,525 |
| Invested Capital | $52,303,115 | $1,699,584 | $12,614,919 | $16,670,648 |
| Working Capital | $79,470,545 | $31,333,292 | $429,175 | $15,530,620 |
| Capital Lease Obligations | $154,362 | $71,859 | $53,316 | $101,706 |
| Total Capitalization | $82,041,436 | $33,404,803 | $2,216,207 | $16,591,230 |
| Minority Interest | $-1,595,343 | $-1,565,834 | $-1,323,881 | $-578,671 |
| Additional Paid In Capital | $28,520,331 | $20,503,904 | $17,510,469 | $16,850,165 |
| Capital Stock | $225,145,216 | $148,065,285 | $92,913,585 | $71,003,225 |
| Common Stock | $195,406,895 | $116,360,066 | $92,913,585 | $71,003,225 |
| Preferred Stock | $29,738,321 | $31,705,219 | $0 | - |
| Long Term Capital Lease Obligation | $75,910 | $0 | $0 | $51,303 |
| Current Capital Lease Obligation | $78,452 | $71,859 | $53,316 | $50,403 |
| Current Accrued Expenses | $4,029,691 | $1,537,546 | $3,026,824 | $2,415,265 |
| Net PPE | $987,126 | $424,916 | $456,247 | $530,750 |
| Accumulated Depreciation | $-644,167 | $-459,690 | $-398,065 | $-292,810 |
| Gross PPE | $1,631,293 | $884,606 | $854,312 | $823,560 |
| Leases | $127,826 | $118,359 | $128,767 | $125,744 |
| Other Properties | $1,269,271 | $626,641 | $571,924 | $560,839 |
| Machinery Furniture Equipment | $234,196 | $139,606 | $153,621 | $136,977 |
| Properties | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $1,493,981 | $858,628 | $513,301 |
| Buildings And Improvements | - | - | - | $89,931 |
| Other Short Term Investments | - | - | - | $0 |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,141,165 | $-30,098,718 | $-20,821,996 | $-14,630,751 |
| Operating Activities | ||||
| Operating Cash Flow | $-28,552,218 | $-29,994,491 | $-20,748,619 | $-14,395,201 |
| Cash Flow From Continuing Operating Activities | $-28,552,218 | $-29,994,491 | $-20,748,619 | $-14,395,201 |
| Operating Gains Losses | $1,568,544 | $137,476 | $-59,763 | $-216,830 |
| Investing Activities | ||||
| Capital Expenditure | $-588,947 | $-104,227 | $-73,377 | $-235,550 |
| Investing Cash Flow | $-588,947 | $-75,159 | $-73,377 | $9,834,371 |
| Cash Flow From Continuing Investing Activities | $-588,947 | $-75,159 | $-73,377 | $9,834,371 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $73,891,109 | $54,558,610 | $15,886,537 | $10,636,577 |
| Financing Cash Flow | $76,058,540 | $45,784,207 | $21,078,966 | $10,801,079 |
| Cash Flow From Continuing Financing Activities | $76,058,540 | $45,784,207 | $21,078,966 | $10,801,079 |
| Net Common Stock Issuance | $73,891,109 | $54,558,610 | $15,886,537 | $10,636,577 |
| Common Stock Issuance | $73,891,109 | $54,558,610 | $15,886,537 | $10,636,577 |
| Other | ||||
| Repayment Of Debt | $0 | $-9,137,464 | $-79,441 | $-142,268 |
| Interest Paid Supplemental Data | $0 | $393,739 | $598,046 | - |
| End Cash Position | $80,563,482 | $33,101,294 | $19,341,756 | $18,263,389 |
| Beginning Cash Position | $33,101,294 | $19,341,756 | $18,263,389 | $12,530,535 |
| Effect Of Exchange Rate Changes | $544,813 | $-1,955,019 | $821,397 | $-507,395 |
| Changes In Cash | $46,917,375 | $15,714,557 | $256,970 | $6,240,249 |
| Proceeds From Stock Option Exercised | $2,167,431 | $363,061 | $5,271,870 | $306,770 |
| Net Issuance Payments Of Debt | $0 | $-9,137,464 | $-79,441 | $-142,268 |
| Net Short Term Debt Issuance | $0 | $-9,074,813 | $0 | - |
| Short Term Debt Payments | $0 | $-9,074,813 | $0 | - |
| Net Long Term Debt Issuance | $0 | $-62,651 | $-79,441 | $-142,268 |
| Long Term Debt Payments | $0 | $-62,651 | $-79,441 | $-142,268 |
| Net PPE Purchase And Sale | $-588,947 | $-75,159 | $-73,377 | $-235,308 |
| Sale Of PPE | $0 | $29,068 | $0 | $242 |
| Purchase Of PPE | $-588,947 | $-104,227 | $-73,377 | $-235,550 |
| Change In Working Capital | $-713,700 | $-6,764,689 | $5,351,763 | $1,514,571 |
| Change In Payables And Accrued Expense | $2,360,643 | $-5,714,878 | $5,577,908 | $1,324,049 |
| Change In Payable | $2,360,643 | $-5,714,878 | $5,577,908 | $1,324,049 |
| Change In Account Payable | $2,360,643 | $-714,878 | $577,908 | $1,324,049 |
| Change In Prepaid Assets | $-2,642,894 | $-948,422 | $-122,435 | $-39,959 |
| Change In Receivables | $-431,449 | $-101,389 | $-103,710 | $230,481 |
| Other Non Cash Items | $-76,945 | $182,569 | $521,008 | $659,951 |
| Stock Based Compensation | $9,037,818 | $3,223,464 | $1,412,257 | $1,433,812 |
| Unrealized Gain Loss On Investment Securities | $0 | $-1,200,541 | $836,595 | $1,056,165 |
| Depreciation Amortization Depletion | $237,717 | $171,719 | $155,527 | $147,894 |
| Depreciation And Amortization | $237,717 | $171,719 | $155,527 | $147,894 |
| Depreciation | $237,717 | $171,719 | $155,527 | $147,894 |
| Net Foreign Currency Exchange Gain Loss | $1,565,982 | $156,087 | $-64,609 | $-223,709 |
| Gain Loss On Sale Of PPE | $2,562 | $-18,611 | $4,846 | $6,879 |
| Net Income From Continuing Operations | $-38,605,652 | $-25,744,489 | $-28,966,006 | $-18,990,764 |
| Net Investment Purchase And Sale | - | - | $0 | $10,069,679 |
| Sale Of Investment | - | - | $0 | $13,342,058 |
| Purchase Of Investment | - | - | $0 | $-3,272,379 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-17